Cargando…
Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer. Surgery is usually curative; however, some locally advanced or metastatic CSCC may be unresectable. Current novel therapeutic options with immune checkpoint inhibition (ICI) of programmed-death receptor 1 (PD-1) such as...
Autores principales: | Lai, Fei Ya, Clarke, Rachel, Cooper, Patrick, Stokes, John, Calvert, Paula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601823/ https://www.ncbi.nlm.nih.gov/pubmed/37900839 http://dx.doi.org/10.1159/000533759 |
Ejemplares similares
-
Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma
por: Marukian, Nareh Valerie, et al.
Publicado: (2020) -
Identifying candidates for immunotherapy with cemiplimab to treat
advanced cutaneous squamous cell carcinoma: an expert opinion
por: Argenziano, Giuseppe, et al.
Publicado: (2022) -
Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
por: Goodman, D.T.
Publicado: (2022) -
Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022) -
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)